11th International Conference on Cryptococcus and Cryptococcosis (ICCC)
第十一届隐球菌和隐球菌病国际会议(ICCC)
基本信息
- 批准号:10399173
- 负责人:
- 金额:$ 1.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdultAffectAfricaAfrica South of the SaharaAfricanAntifungal AgentsAntifungal TherapyArchivesAreaBasic ScienceBotswanaCOVID-19 pandemicCaringCentral Nervous System InfectionsCessation of lifeCharacteristicsClinicalClinical InvestigatorClinical SciencesClinical TrialsCollaborationsCommunicable DiseasesCommunitiesCountryCryptococcal MeningitisCryptococcosisCryptococcusCryptococcus neoformansDiseaseEtiologyFaceFailureFamilyFloorFosteringFundingFutureGenomeGoalsGrantHIVHIV antiretroviralImmune systemImmunityImmunocompetentImmunocompromised HostImmunosuppressionIncidenceIncomeInternationalInternational AspectsInvadedKnowledgeMedicalMeningitisMicrobiologyMinorityMolecularMorbidity - disease rateMycosesOpportunistic InfectionsOralParticipantPathogenesisPathogenicityPatientsPersonsPostdoctoral FellowPredispositionPrevention strategyProgram DevelopmentPropertyRequest for ProposalsResearchResearch PersonnelResourcesRetroviridae InfectionsRiskScientific Advances and AccomplishmentsScientistSexual ReproductionSignal TransductionSiteSouth AfricaStructureStudentsThe science of MycologyTimeTranslational ResearchTravelTwitterUgandaUnderrepresented MinorityUnited States National Institutes of HealthVirulenceWheelchairsWomanantiretroviral therapycareerclinical practicedigitalfungusgraduate studentinnovationmeetingsmortalityneglectnovelpandemic diseaseparitypathogenpost-COVID-19posterspreclinical developmentprogramsscreeningsocial mediasymposiumtherapy developmenttooltreatment strategyvaccine developmentweb siteworking group
项目摘要
ABSTRACT
This proposal requests partial support for the 11th International Conference on Cryptococcus and
Cryptococcosis (ICCC) to be held in Kampala, Uganda, January 10-14, 2022. Cryptococcosis accounts for
15% of AIDS-related deaths globally. Cryptococcal meningitis remains the most common neuroinfection
among all adults in Sub-Saharan Africa and continues to be a major threat to a growing number of non-HIV
immunocompromised persons.
The broad and long-term goal of this ICCC is to bring together the world's leading researchers in this
expanding field to foster cross-disciplinary discussions, research, and clinical collaborations to enhance our
understanding of the mechanisms of Cryptococcus pathogenicity and best management of cryptococcosis.
The specific aims of this meeting will be to convene leading experts whose expertise covers critical
areas within this field, as well as early career and junior investigators, students, and postdocs. We
anticipate hosting 300 participants. The program will be structured into 17 sessions covering the diverse
properties and characteristics of the pathogen as well as host susceptibility and immunity, emphasizing
what makes a normal host suddenly susceptible to this disease. Importantly, the conference will provide
ample coverage of current and novel antifungals – ranging from pre-clinical development programs through
ongoing/future clinical trials. Abstracts from junior investigators, graduate students, and postdoctoral fellows
will be included among those selected for oral presentation. The conference will host two poster sessions
which will permit all participants to actively contribute to these topics. Of the 17 session blocks, 12 blocks
will be concurrent sessions to allow for smaller working groups to meet and more students / trainees to
present their abstracts. The R13 resources will go towards supporting travel grant participation by graduate
students and specifically under-represented minority scholars from US and Africa who present abstracts.
We will seek parity with respect to women and minorities in the selection of speakers and organizing
committee, starting with 2 of the 3 ICCC co-chairs being a woman or a minority. We will target at least
~40% of plenary speakers to be women and ~10% under-represented minorities. Childcare will be provided.
The 11th ICCC is significant because focuses on an important infectious disease afflicting both
immunocompromised and immunocompetent people. This is the only such conference that brings together
basic scientists and clinical investigators who investigate cryptococcosis. This is the first time the
conference will be held in Africa with objectives: 1) to build new US-African translational research
collaborations; 2) to define the important clinical, translational, and basic science research agenda to forge
new avenues for novel prevention and treatment strategies.
摘要
该提案要求部分支持第11届国际隐球菌会议,
隐球菌病(ICCC)将于2022年1月10日至14日在乌干达坎帕拉举行。隐球菌病
全球15%的艾滋病相关死亡。隐球菌脑膜炎仍然是最常见的神经感染
在撒哈拉以南非洲的所有成年人中,艾滋病毒仍然是越来越多的非艾滋病毒感染者的主要威胁。
免疫力低下的人。
ICCC的广泛和长期目标是汇集世界领先的研究人员,
扩大领域,促进跨学科的讨论,研究和临床合作,以提高我们的
了解隐球菌的致病机制和隐球菌病的最佳治疗。
这次会议的具体目标是召集主要专家,他们的专门知识涉及关键领域,
在这个领域内的领域,以及早期的职业生涯和初级研究人员,学生和博士后。我们
预计接待300名与会者。该计划将分为17个会议,涵盖不同的
病原体的性质和特点以及宿主的易感性和免疫力,强调
是什么让一个正常的宿主突然对这种疾病易感重要的是,会议将提供
广泛覆盖当前和新型抗真菌药物-从临床前开发项目到
正在进行/未来的临床试验。初级研究人员、研究生和博士后研究员的摘要
将被列入口头报告的候选人名单。会议将举办两次海报会议
这将使所有参与者都能对这些主题作出积极贡献。在17个会话块中,12个块
将同时举行会议,以允许较小的工作组开会,更多的学生/学员
介绍他们的摘要。R13资源将用于支持研究生参加旅行补助金
学生,特别是来自美国和非洲的少数民族学者,他们提交了摘要。
我们将在选择发言人和组织会议方面争取妇女和少数民族的平等。
委员会的三名共同主席中有两名是妇女或少数民族。我们至少要瞄准
全体会议发言人中约40%为妇女,约10%为代表不足的少数民族。将提供托儿服务。
第11届ICCC意义重大,因为重点关注困扰双方的一种重要传染病
免疫力低下和免疫力正常的人。这是唯一一次这样的会议,
研究隐球菌病的基础科学家和临床研究者。这是第一次
会议将在非洲举行,目标:1)建立新的美国-非洲转化研究
合作; 2)确定重要的临床,转化和基础科学研究议程,以建立
新的预防和治疗策略的新途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David R Boulware其他文献
Management of advanced HIV disease in Africa
非洲艾滋病晚期的管理
- DOI:
10.1016/s2352-3018(23)00078-4 - 发表时间:
2023-06-01 - 期刊:
- 影响因子:13.000
- 作者:
Santiago Izco;Alberto L Garcia-Basteiro;David W Denning;David R Boulware;Adam Penn-Nicholson;Emilio Letang - 通讯作者:
Emilio Letang
Experiences, challenges, gaps, and strategies for counselling persons presenting with advanced HIV-associated meningitis in Uganda
- DOI:
10.1186/s12981-025-00705-z - 发表时间:
2025-02-19 - 期刊:
- 影响因子:2.500
- 作者:
Alisat Sadiq;Richard Kwizera;Tadeo K Kiiza;Peruth Ayebare;Cynthia Ahimbisibwe;Jane Frances Ndyetukira;David R Boulware;David B. Meya - 通讯作者:
David B. Meya
Randomized trial of mechanotherapy for the treatment of stress urinary incontinence in women
机械疗法治疗女性压力性尿失禁的随机试验
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:2
- 作者:
Nissrine A. Nakib;Suzette Sutherland;Kevin Hallman;Marcus Mianulli;David R Boulware - 通讯作者:
David R Boulware
Advancing the chemotherapy of tuberculous meningitis: a consensus view
推进结核性脑膜炎的化疗:共识观点
- DOI:
10.1016/s1473-3099(24)00512-7 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:31.000
- 作者:
Sean Wasserman;Joseph Donovan;Evelyne Kestelyn;James A Watson;Robert E Aarnoutse;James R Barnacle;David R Boulware;Felicia C Chow;Fiona V Cresswell;Angharad G Davis;Kelly E Dooley;Anthony A Figaji;Diana M Gibb;Julie Huynh;Darma Imran;Suzaan Marais;David B Meya;Usha K Misra;Manish Modi;Mihaja Raberahona;Robert J Wilkinson - 通讯作者:
Robert J Wilkinson
Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trials
用于隐球菌性脑膜炎死亡率的个性化风险预测工具以指导撒哈拉以南非洲的治疗分层:一项基于两项随机对照试验汇总分析的预后建模研究
- DOI:
10.1016/s2214-109x(25)00010-5 - 发表时间:
2025-05-01 - 期刊:
- 影响因子:18.000
- 作者:
Thomas H A Samuels;Sile F Molloy;David S Lawrence;Angela Loyse;Cecilia Kanyama;Robert S Heyderman;Wai Shing Lai;Sayoki Mfinanga;Sokoine Lesikari;Duncan Chanda;Charles Kouanfack;Elvis Temfack;Olivier Lortholary;Mina C Hosseinipour;Adrienne K Chan;David B Meya;David R Boulware;Henry C Mwandumba;Graeme Meintjes;Conrad Muzoora;Rishi K Gupta - 通讯作者:
Rishi K Gupta
David R Boulware的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David R Boulware', 18)}}的其他基金
Encochleated Oral Amphotericin for HIV-related Cryptococcal Meningitis Trial: Phase 3 Trial
包埋口服两性霉素治疗 HIV 相关隐球菌性脑膜炎试验:3 期试验
- 批准号:
10619788 - 财政年份:2023
- 资助金额:
$ 1.7万 - 项目类别:
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies
结核性脑膜炎:评估脑脊液免疫学以发现隐藏疾病和潜在的免疫调节疗法
- 批准号:
10459614 - 财政年份:2021
- 资助金额:
$ 1.7万 - 项目类别:
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies
结核性脑膜炎:评估脑脊液免疫学以发现隐藏疾病和潜在的免疫调节疗法
- 批准号:
10335501 - 财政年份:2021
- 资助金额:
$ 1.7万 - 项目类别:
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies
结核性脑膜炎:评估脑脊液免疫学以发现隐藏疾病和潜在的免疫调节疗法
- 批准号:
10675513 - 财政年份:2021
- 资助金额:
$ 1.7万 - 项目类别:
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial
包埋口服两性霉素治疗隐球菌性脑膜炎试验
- 批准号:
10163929 - 财政年份:2019
- 资助金额:
$ 1.7万 - 项目类别:
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial
包埋口服两性霉素治疗隐球菌性脑膜炎试验
- 批准号:
10364704 - 财政年份:2019
- 资助金额:
$ 1.7万 - 项目类别:
Cryptococcal Antigen Screening plus Sertraline (C-ASSERT)
隐球菌抗原筛查加舍曲林 (C-ASSERT)
- 批准号:
9271847 - 财政年份:2016
- 资助金额:
$ 1.7万 - 项目类别:
Phased Implementation of a Public Health Programme: Cryptococcal Screening and Treatment in South Africa
公共卫生计划的分阶段实施:南非的隐球菌筛查和治疗
- 批准号:
9232071 - 财政年份:2016
- 资助金额:
$ 1.7万 - 项目类别:
Cryptococcal Antigen Screening plus Sertraline (C-ASSERT)
隐球菌抗原筛查加舍曲林 (C-ASSERT)
- 批准号:
9925177 - 财政年份:2016
- 资助金额:
$ 1.7万 - 项目类别:
Cryptococcal Antigen Screening plus Sertraline (C-ASSERT)
隐球菌抗原筛查加舍曲林 (C-ASSERT)
- 批准号:
9914429 - 财政年份:2016
- 资助金额:
$ 1.7万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 1.7万 - 项目类别:
Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 1.7万 - 项目类别:
Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 1.7万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 1.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 1.7万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 1.7万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 1.7万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 1.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 1.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 1.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




